Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Acitretin
Drug ID BADD_D00036
Description An oral retinoid effective in the treatment of psoriasis. It is the major metabolite of etretinate with the advantage of a much shorter half-life when compared with etretinate.
Indications and Usage Zouboulis CC: Retinoids--which dermatological indications will benefit in the near future? Skin Pharmacol Appl Skin Physiol. 2001 Sep-Oct;14(5):303-15.
Marketing Status Prescription; Discontinued
ATC Code D05BB02
DrugBank ID DB00459
KEGG ID D02754
MeSH ID D017255
PubChem ID 5284513
TTD Drug ID D05QDC
NDC Product Code 42291-088; 0145-0091; 17337-0004; 76055-0001; 71214-0668; 0093-1136; 0093-1135; 58159-058; 42794-081; 42794-080; 0093-1138; 0145-0090; 62147-0145; 42794-083; 42291-086; 71214-0667; 71214-0669; 0378-7020; 0115-1750; 0115-1751; 0115-1752; 71214-0698; 42291-087; 62147-0146; 0378-7023; 17337-0003; 59981-011; 0115-1753
Synonyms Acitretin | Etretin | Isoacitretin | Isoetretin | Ro 10-1670 | Ro 101670 | Ro-10-1670 | Ro101670 | 13-cis-Acitretin | Neotigason | Soriatane | Acitretin, (Z,E,E,E)-Isomer | Ro-13-7652 | Ro137652 | Ro 13-7652 | Ro 137652
Chemical Information
Molecular Formula C21H26O3
CAS Registry Number 55079-83-9
SMILES CC1=CC(=C(C(=C1C=CC(=CC=CC(=CC(=O)O)C)C)C)C)OC
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Vitamin D deficiency14.12.03.0030.005728%Not Available
VIth nerve paralysis17.04.02.002; 06.05.02.0090.008592%Not Available
Vomiting07.01.07.003--
Vulvovaginitis21.14.02.005; 11.01.10.003--Not Available
Weight decreased13.15.01.005--
Weight increased13.15.01.006--
White blood cell count decreased13.01.06.012--
White blood cell count increased13.01.06.013--Not Available
White blood cells urine positive13.13.02.004--Not Available
Xerophthalmia14.12.03.002; 06.06.03.008--Not Available
Joint range of motion decreased15.01.02.0060.005728%
Onychoclasis23.02.05.005--Not Available
Osteopenia15.02.03.003; 14.04.04.0040.008592%Not Available
Blood phosphorus decreased13.11.01.015--Not Available
Blood phosphorus increased13.11.01.016--Not Available
Cerumen impaction04.01.01.001--Not Available
Band neutrophil count increased13.01.06.031--Not Available
Deep vein thrombosis24.01.02.0030.011456%Not Available
Self-injurious ideation19.12.01.007--Not Available
Madarosis23.02.02.004; 06.06.04.010--Not Available
Platelet count increased13.01.04.002--Not Available
Eyelids pruritus23.03.12.005; 06.08.03.007--Not Available
Sticky skin23.03.03.019--Not Available
Eye pruritus06.04.05.006--Not Available
Adenocarcinoma pancreas16.13.10.002; 07.21.09.003--Not Available
Drug tolerance decreased08.06.01.024--Not Available
Protein urine present13.13.02.006--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Senile ankylosing vertebral hyperostosis15.01.04.005--Not Available
Transaminases increased13.03.01.0150.008592%Not Available
The 11th Page    First    Pre   11 12 13    Next   Last    Total 13 Pages